Insider Selling: Milestone Pharmaceuticals (NASDAQ:MIST) COO Sells 12,245 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) COO Jeffrey Edward Nelson sold 12,245 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $23,632.85. Following the sale, the chief operating officer owned 49,848 shares of the company’s stock, valued at approximately $96,206.64. This represents a 19.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey Edward Nelson also recently made the following trade(s):

• On Monday, December 15th, Jeffrey Edward Nelson sold 58,007 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.32, for a total value of $134,576.24.

Milestone Pharmaceuticals Stock Performance

MIST traded down $0.07 during trading on Wednesday, hitting $1.94. The stock had a trading volume of 1,697,941 shares, compared to its average volume of 3,110,069. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. The company has a 50 day moving average price of $2.23 and a 200-day moving average price of $1.96. Milestone Pharmaceuticals Inc. has a one year low of $0.63 and a one year high of $3.06. The firm has a market cap of $165.23 million, a price-to-earnings ratio of -2.37 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. As a group, research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current year.

Milestone Pharmaceuticals News Summary

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone launched CARDAMYST nasal spray for U.S. pharmacy availability — a commercial milestone that could begin to drive product revenue and awareness. Milestone Launches CARDAMYST Nasal Spray in U.S. Pharmacies
• Positive Sentiment: Analyst optimism rose after Zacks upgraded MIST from “Hold” to a “Strong Buy” (Zacks Rank #1), which may attract buyers and short?term momentum flows. All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
• Neutral Sentiment: Trading context: shares are trading below the 50?day moving average and volume is below the stock’s average, which can mute a sustained bounce despite the product launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto completed sizeable stock sales: 133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93 — material reductions disclosed to the SEC that may worry investors about insider confidence or trigger selling pressure. SEC Form 4 – Joseph Oliveto
• Negative Sentiment: Other insiders (David Bharucha and Lorenz Muller) also sold large blocks on both Dec. 15 (~58k and ~53.6k shares respectively) and Jan. 26 (~12.2k and ~11.2k shares respectively), representing substantial percentage reductions in their holdings. These clustered insider sales intensify negative sentiment. SEC Form 4 – David Bharucha SEC Form 4 – Lorenz Muller
• Negative Sentiment: COO Jeffrey Nelson similarly sold significant shares on Dec. 15 and Jan. 26 (including ~58k on Dec. 15), cutting his stake materially — another factor pressuring sentiment. SEC Form 4 – Jeffrey Edward Nelson

Wall Street Analyst Weigh In

MIST has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.00.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Propel Bio Management LLC boosted its holdings in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC acquired a new position in shares of Milestone Pharmaceuticals during the 3rd quarter worth $6,444,000. Simplify Asset Management Inc. lifted its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after buying an additional 1,842,974 shares during the last quarter. Pathstone Holdings LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at about $2,000,000. Finally, Boxer Capital Management LLC bought a new position in Milestone Pharmaceuticals in the third quarter valued at about $1,333,000. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.